Paola Valsasina1, Maria A. Rocca1,2, Alessandro Meani1, Claudio Gobbi3, Chiara Zecca3, Alex Rovira4, Xavier Montalban5, Hugh Kearney6, Olga Ciccarelli6, Lucy Matthews7, Jacqueline Palace7, Antonio Gallo8, Alvino Bisecco8, Carsten Lukas9, Barbara Bellenberg9, Frederik Barkhof10,11, Hugo Vrenken10, Paolo Preziosa1,2, and Massimo Filippi1,2,12
1Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy, 2Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, 3Department of Neurology, Neurocenter of Southern Switzerland, Civic Hospital, Lugano, Switzerland, 4Section of Neuroradiology and MRI Unit, Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain, 5Department of Neurology/Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d'Hebron, Barcelona, Spain, 6NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom, 7Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom, 8Department of Advanced Medical and Surgical Sciences, and 3T MRI Center, University of Campania “Luigi Vanvitelli”, Naples, Italy, 9Department of Radiology and Nuclear Medicine, and Institute of Neuroradiology, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany, 10Department of Radiology and Nuclear Medicine, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, Netherlands, 11Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom, 12Vita-Salute San Raffaele University, Milan, Italy
Synopsis
In this study, we used source-based
morphometry to identify patterns of grey matter tissue loss in a large,
multicenter cohort of patients with multiple sclerosis (MS) acquired at 8
European sites. We detected a differential involvement of grey matter networks across the different
stages of the disease. Cortical and subcortical grey matter atrophy progressed
significantly in MS patients over 1-year of follow-up. Grey matter atrophy, especially in the sensorimotor network, was able to
explain patients’ clinical disability, while cerebellar atrophy was able to
predict clinical disability worsening over 1-year follow-up.
Introduction
Grey matter (GM) involvement
been recognized to be a crucial component of multiple sclerosis (MS)
pathophysiology [1]. Source-based morphometry (SBM) is a method able to do a
multivariate GM decomposition into co-varying patterns of GM density [2]. Aim of this study was to characterize atrophy
of GM patterns across different stages of MS, and its evolution over 1-year
follow-up, by analyzing a large, multicentre dataset acquired at 8 European sites.Methods
MRI
and clinical evaluations were obtained from 170 healthy controls (HC) and 398
MS patients (34 clinically isolated syndromes [CIS], 226 relapsing-remitting
[RR], 95 secondary progressive [SP] and 43 primary progressive [PP] MS). Fifty-seven
HC and 144 MS patients underwent 1-year follow-up. At follow-up, patients were
classified as clinically stable or worsened, according to changes in the
Expanded Disability Status Scale (EDSS) score [3]. Baseline GM loss,
longitudinal GM atrophy changes, and correlations with disability and 1-year
clinical worsening were assessed.Results
SBM identified 26 relevant GM components, which
were assigned to cerebellar, subcortical, sensorimotor, visual, temporal,
default-mode, fronto-parietal, hippocampal, executive and salience networks
(Figure 1). Compared to HC, MS patients showed significant GM atrophy in almost
all components (p=range <0.001-0.04). CIS patients showed circumscribed GM atrophy
in subcortical, cerebellar, temporal and salience components vs HC, while RRMS patients exhibited
widespread GM atrophy involving most GM components (Figure 2). PPMS patients
showed GM loss vs HC mainly located
in cerebellar, subcortical, sensorimotor, salience and fronto-parietal regions
(Figure 2). Such components showed additional GM atrophy in SPMS vs RRMS. At 1-year, 21 (15%) MS patients
had clinically worsened. GM atrophy significantly progressed over time in MS
patients in subcortical, cerebellar, sensorimotor, temporal and fronto-parietal
regions (Figure 3). Baseline higher disability was associated (R2=0.65)
with lower normalized brain volume (b=-0.13, p=0.001), higher sensorimotor GM loss (b=-0.12, p=0.002) and
longer disease duration (b=0.09, p=0.04). Normalized GM volume (odds ratio=0.98, p=0.008) and cerebellar
GM volume (odds ratio=0.40, p=0.01) were independent predictors of clinical
worsening (area-under-the-curve=0.83).Discussion
In our
study, we found widespread GM atrophy, which
started from subcortical and cerebellar networks at the earliest disease
stages, and progressively spread to cortical areas, especially those involved
in sensory and motor functions. Diffuse GM loss became more severe in progressive
than in relapsing MS patients. Also, GM atrophy significantly progressed over
time in MS patients in distinct structural systems. Sensorimotor and cerebellar GM atrophy were able to explain baseline
disability and clinical worsening.Conclusions
SBM highlighted a
differential regional GM involvement across disease stages and significant
atrophy progression at 1-year in MS patients. Neuroprotection
therapies or neurorehabilitative programs targeting vulnerable regions might be
particularly valuable in MS patients to counteract MS-related damage and stop
disease progression.Acknowledgements
The authors, for the MAGNIMS Study GroupReferences
[1] Filippi M., et al. Curr Opin
Neurol, 2014. 27: 290-299.
[2] Xu L., et
al. Hum Brain Mapp, 2009. 30: 711-724.
[3] Filippi,
M., et al. Neurology, 2013. 81: 1759-1767.